Vaxon Biotech SA Appoints Founder And Chief Scientific Officer, Dr. Konstantinos Kosmatopoulos, As CEO
Paris, France, March 30, 2015 - Vaxon Biotech, a company specialized in anti-tumor immunotherapy, today announces the appointment of company founder Dr. Konstantinos (Kostas) Kosmatopoulos, MD, PhD, as CEO. Kostas moves from his current role as chief scientific officer.
He will use his experience as a medical oncologist and immunologist to lead the company forward during a very active period.
In 2015 and 2016, Vaxon Biotech will announce the results of several current studies: the completion of patient recruitment in its Vx-001-201 randomized study, the final results of the large Vx-006-101 phase I study, completion of preclinical development of the Vbx-016 that will enter a phase I trial and the initiation of preclinical development of the Vbx-026 vaccine.
Kostas established Vaxon Biotech in 2004 on the basis of his work as research director at Inserm, France’s national institute of health, and his work specializing in tumor immunotherapy at Institut Gustave Roussy (IGR), a leading cancer research institute. The two institutes granted Vaxon Biotech an exclusive worldwide license for three patents. The company subsequently filed seven more patents in its own name.
Kostas received his medical degree at the University of Thessaloniki, his medical oncology certification from Theagenion Cancer Research Institute, Greece, and his PhD in Immunology at Paris XI University, France. Dr. Kosmatopoulos has co-authored more than 50 scientific and international publications including his most recent in Clin. Lung Cancer (2013, 14, 461)
“I am very enthusiastic and delighted to hold this new position at Vaxon Biotech, the company I founded ten years ago,” said Kostas Kosmatopoulos. “I have always been convinced of its potential in anti-tumor immunotherapy, a very promising sector in oncology. Using all my knowledge and experience I will continue to work towards Vaxon achieving its goals and speeding up its activity.”
Vaxon Biotech develops unique and innovative vaccine technology. The company uses ‘optimized cryptic peptides’ that significantly improve immune responses and therefore vaccine efficacy.
About Vaxon Biotech
Vaxon Biotech specializes in anti-tumor immunotherapy through an innovative therapeutic approach. This approach aims to stimulate the immune system to target and destroy tumor cells, halting tumor development. ?The company is currently developing four products, two in clinical development and two at the preclinical stage. The most advanced product in its portfolio, Vx-001, is a peptide based vaccine for HLA-A2-positive patients with TERT-expressing tumors. It has been in phase IIB trials for non-small-cell lung cancer (NSCLC) in eight European countries since 2012.
Vaxon Biotech is also developing another product, Vx-006, a polypeptide designed to treat solid tumors. This product is currently in a phase I clinical study that aims to evaluate toxicity and measure the immune response induced by Vx-006. The results of the study will be made public in late 2015.
Based in Paris and Evry, France, Vaxon Biotech was founded in 2004 on the basis of work undertaken by Dr Kostas Kosmatopoulos at Inserm, France’s national institute of health and medical research, and the Institut Gustave Roussy (IGR), a leading cancer research institute. The two institutes have granted Vaxon Biotech an exclusive worldwide license for three patents, with the company having subsequently filed seven more patents in its own name.
ANR (French Agence Nationale de la Recherche) has subsidized the initial R&D for Vbx-016 and Vbx-026. GENOPOLE-Evry and INSERM-Transfert have supported Vaxon Biotech since its inception; they are both historical shareholders in the company.
http://www.vaxon-biotech.com
Help employers find you! Check out all the jobs and post your resume.
He will use his experience as a medical oncologist and immunologist to lead the company forward during a very active period.
In 2015 and 2016, Vaxon Biotech will announce the results of several current studies: the completion of patient recruitment in its Vx-001-201 randomized study, the final results of the large Vx-006-101 phase I study, completion of preclinical development of the Vbx-016 that will enter a phase I trial and the initiation of preclinical development of the Vbx-026 vaccine.
Kostas established Vaxon Biotech in 2004 on the basis of his work as research director at Inserm, France’s national institute of health, and his work specializing in tumor immunotherapy at Institut Gustave Roussy (IGR), a leading cancer research institute. The two institutes granted Vaxon Biotech an exclusive worldwide license for three patents. The company subsequently filed seven more patents in its own name.
Kostas received his medical degree at the University of Thessaloniki, his medical oncology certification from Theagenion Cancer Research Institute, Greece, and his PhD in Immunology at Paris XI University, France. Dr. Kosmatopoulos has co-authored more than 50 scientific and international publications including his most recent in Clin. Lung Cancer (2013, 14, 461)
“I am very enthusiastic and delighted to hold this new position at Vaxon Biotech, the company I founded ten years ago,” said Kostas Kosmatopoulos. “I have always been convinced of its potential in anti-tumor immunotherapy, a very promising sector in oncology. Using all my knowledge and experience I will continue to work towards Vaxon achieving its goals and speeding up its activity.”
Vaxon Biotech develops unique and innovative vaccine technology. The company uses ‘optimized cryptic peptides’ that significantly improve immune responses and therefore vaccine efficacy.
About Vaxon Biotech
Vaxon Biotech specializes in anti-tumor immunotherapy through an innovative therapeutic approach. This approach aims to stimulate the immune system to target and destroy tumor cells, halting tumor development. ?The company is currently developing four products, two in clinical development and two at the preclinical stage. The most advanced product in its portfolio, Vx-001, is a peptide based vaccine for HLA-A2-positive patients with TERT-expressing tumors. It has been in phase IIB trials for non-small-cell lung cancer (NSCLC) in eight European countries since 2012.
Vaxon Biotech is also developing another product, Vx-006, a polypeptide designed to treat solid tumors. This product is currently in a phase I clinical study that aims to evaluate toxicity and measure the immune response induced by Vx-006. The results of the study will be made public in late 2015.
Based in Paris and Evry, France, Vaxon Biotech was founded in 2004 on the basis of work undertaken by Dr Kostas Kosmatopoulos at Inserm, France’s national institute of health and medical research, and the Institut Gustave Roussy (IGR), a leading cancer research institute. The two institutes have granted Vaxon Biotech an exclusive worldwide license for three patents, with the company having subsequently filed seven more patents in its own name.
ANR (French Agence Nationale de la Recherche) has subsidized the initial R&D for Vbx-016 and Vbx-026. GENOPOLE-Evry and INSERM-Transfert have supported Vaxon Biotech since its inception; they are both historical shareholders in the company.
http://www.vaxon-biotech.com
Help employers find you! Check out all the jobs and post your resume.